We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
CV Therapeutics (MM) | NASDAQ:CVTX | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 20.01 | 0 | 01:00:00 |
FORM 4
[
X
]
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue.
See
Instruction 1(b).
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
|
OMB APPROVAL
OMB Number: 3235-0287 Expires: February 28, 2011 Estimated average burden hours per response... 0.5 |
|
Utility Holding Company Act of 1935 or Section 30(f) of the Investment Company Act of 1940 |
|
1. Name and Address of Reporting Person
*
SPIEGELMAN DANIEL K |
2. Issuer Name
and
Ticker or Trading Symbol
CV THERAPEUTICS INC [ CVTX ] |
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
_____ Director _____ 10% Owner __ X __ Officer (give title below) _____ Other (specify below) SVP, CFO |
3172 PORTER DRIVE |
3. Date of Earliest Transaction
(MM/DD/YYYY)
|
|
PALO ALTO, CA 94304 |
4. If Amendment, Date Original Filed
(MM/DD/YYYY)
|
6. Individual or Joint/Group Filing
(Check Applicable Line)
_ X _ Form filed by One Reporting Person ___ Form filed by More than One Reporting Person |
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned |
||||||||||
1.Title of Security
(Instr. 3) |
2. Trans. Date | 2A. Deemed Execution Date, if any |
3. Trans. Code
(Instr. 8) |
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) |
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4) |
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Indirect Beneficial Ownership (Instr. 4) | |||
Code | V | Amount | (A) or (D) | Price | ||||||
Common Stock | 67785 (1) | D | ||||||||
Common Stock | 6673.9084 | I | By 401(k) (2) |
Table II - Derivative Securities Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities) |
|||||||||||||||
1. Title of Derivate Security
(Instr. 3) |
2. Conversion or Exercise Price of Derivative Security | 3. Trans. Date | 3A. Deemed Execution Date, if any |
4. Trans. Code
(Instr. 8) |
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) |
6. Date Exercisable and Expiration Date |
7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4) |
8. Price of Derivative Security
(Instr. 5) |
9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) | 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) | ||||
Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | ||||||||
Employee Stock Option (right to buy) | $10.45 | 4/16/2009 | M | 88542 | 9/22/2007 (3) | 8/22/2017 | Common Stock | 88542 | $9.55 | 0 | D |
Explanation of Responses: | |
( 1) | Includes 296 shares acquired April 14, 2009 pursuant to the CV Therapeutics, Inc. Employee Stock Purchase Plan ("ESPP"). |
( 2) | Shares held in the Reporting Person's name by the Issuer's 401(k) plan. |
( 3) | This option to purchase shares of the Issuer's stock, which provided that 1/36th of the shares subject to the option grant shall vest on the 22nd day of each calendar month following the August 22, 2007 date of grant, became 100% vested and exercisable due to a change in control of the Issuer effected through the tender offer by Apex Merger Sub, Inc. ("Apex"), a wholly owned subsidiary of Gilead Sciences, Inc. ("Gilead), effective as of April 16, 2009. The Issuer will make a cash payment of $845,576.10, representing the gross cash amount, less applicable withholding, for the remaining shares subject to this option which became 100% vested and exercisable due to the change in control, to the Reporting Party. |
Reporting Owners
|
|||||
Reporting Owner Name / Address |
|
||||
Director | 10% Owner | Officer | Other | ||
SPIEGELMAN DANIEL K
3172 PORTER DRIVE PALO ALTO, CA 94304 |
|
|
SVP, CFO |
|
Signatures
|
||
/S/ TRICIA BORGA SUVARI, ATTORNEY IN FACT FOR: DANIEL K SPIEGELMAN | 4/17/2009 | |
** Signature of Reporting Person |
Date
|
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. | |
* | If the form is filed by more than one reporting person, see Instruction 4(b)(v). |
** | Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). |
Note: | File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. |
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number. |
1 Year CV Therapeutics Chart |
1 Month CV Therapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions